Abstract

The aim of the report was to evaluate the impact of soy protein containing isoflavones and soy isoflavones extract on lipid profile in postmenopausal women, as compared with placebo or protein of milk, casein or isolated soy protein with or without trace isoflavone content. We used the following databases: MEDLINE (PubMed), EMBASE and the Cochrane Library. Quantitative data synthesis was performed by applying a random-effects model. Subgroup analysis and meta-regression were performed to assess the modifiers of treatment response. In total, in the analysis studies, 2305 postmenopausal women took part. Changes in the lipid profile showed statistically significant decreases of total cholesterol by −0.12 (95% CI: −0.21, −0.03) mmol/L, −4.64 (95% CI: −8.12, −1.16) mg/dL, p = 0.01 and increased HDL-cholesterol by 0.03 (95% CI: 0.00, 0.06) mmol/L, 1.15 (95% CI: 0.00, 1.93) mg/dL, p = 0.05, as well as in LDL-cholesterol −0.05 (95% CI: −0.11, 0.01) mmol/L, −1.93 (95% CI: −4.25, 0.39) mg/dL, p = 0.08 and triacylglycerols −0.07 (95% CI: −0.14, 0.00) mmol/L, −6.123 (95% CI: −12.25, 0.00) mg/dL, p = 0.06. Our results suggests that soy and its isoflavones can be effective in correction changes in lipid metabolism in postmenopausal women and may favorably influence in preventing cardiovascular events.

Highlights

  • In our systematic review and meta-analysis, we focused on the assessment of the effect of isolates of soy protein rich in isoflavones, as well as soy isoflavones extract on the lipid profile in postmenopausal women

  • 83 potenrelevant clinical trials were qualified for further analysis inanalysis the full-text tially relevant clinical trials were qualified fordetailed further qualitative detailed qualitative in the assessment

  • Our meta-analysis looked at 29 trials with 32 comparisons assessing the influence of isolated soy protein containing isoflavones and/or of soy isoflavones extract on individual components of lipid profiles

Read more

Summary

Introduction

After natural menopause or bilateral ovariectomy, as a result of estrogen deficiency, a progress of changes in the metabolism of women is observed This leads to an incidence of many metabolic syndrome features, including accumulation of fat mass in the abdominal compartment, transition to a more atherogenic lipid profile, hyperinsulinemia, insulin resistance and glucose intolerance [2,3,4,5]. During the menopausal transition (within the 1-year interval before and after the final menstrual period), a substantial increase of total cholesterol (TC), LDL-cholesterol (LDL-C) and apolipoprotein B has been demonstrated This is associated with decreased circulating estrogen levels [8]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call